Form 4: Metagenomi GC Wein Reports Stock Transactions

Metagenomi General Counsel Matthew Wein reported recent stock transactions, including a tax-related sale, ESPP acquisitions, and a significant RSU grant.

Summary

• Matthew Wein, General Counsel, Compliance Officer, and Corporate Secretary of Metagenomi, Inc. (MGX), reported changes in his beneficial ownership.
• On September 5, 2025, 199 shares of common stock were automatically sold at $1.81 per share to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs) granted on April 1, 2024.
• On December 1, 2025, Mr. Wein was granted 96,000 Restricted Stock Units (RSUs) at a price of $1.6 per share.
• These RSUs will vest 50% on December 5, 2026, and the remaining 50% on December 5, 2027, contingent on his continued service.
• His beneficial ownership following these transactions is 115,230 shares of common stock, which includes 1,359 shares acquired via the Company's employee stock purchase plan (ESPP) on May 30, 2025, and 1,377 shares acquired via ESPP on November 28, 2025.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of insider transactions, including both a non-volitional sale for tax purposes and a significant RSU grant, indicating a neutral overall sentiment regarding company performance or outlook.

Positives

• The reporting person received a grant of 96,000 Restricted Stock Units (RSUs), indicating continued compensation and alignment with company performance.
• Acquisition of 2,736 shares (1,359 + 1,377) through the Employee Stock Purchase Plan (ESPP) demonstrates ongoing participation in employee benefit programs.

Negatives

• A sale of 199 shares of common stock occurred, although it was non-volitional and for tax withholding purposes related to RSU vesting.

Future Outlook

The vesting schedule for the granted Restricted Stock Units (RSUs) on December 5, 2026, and December 5, 2027, indicates an expectation of continued service by the reporting person with Metagenomi, Inc. through these dates.

Management Comments

• The sale of 199 shares of common stock was automatically executed for the purpose of satisfying tax withholding obligations upon the vesting of certain restricted stock units and does not represent a volitional trade by the Reporting Person.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, common across all publicly traded companies. It provides transparency into how key executives manage their equity compensation and holdings, which is a standard practice in corporate governance and executive compensation within the biotechnology or pharmaceutical industry where Metagenomi operates.

Stakeholder Impact

• Shareholders: Provides transparency into the equity holdings and compensation activities of a key executive, which can influence investor perception of insider alignment and confidence.

Next Steps

• Continued service of the reporting person with the Issuer for RSU vesting on December 5, 2026.
• Continued service of the reporting person with the Issuer for RSU vesting on December 5, 2027.

Key Dates

Keywords

Metagenomi, MGX, Form 4, Insider Transaction, Restricted Stock Units, RSU, Employee Stock Purchase Plan, ESPP, Matthew Wein, Stock Sale, Stock Grant